Capital Impact Advisors, LLC Neurocrine Biosciences Inc Transaction History

Capital Impact Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $1.7 Million - $2.26 Million	-21,305 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $275,000 - $316,004	-3,191 Reduced 13.03%	21,305 $2.04 Million
Q2 2021 Aug 17, 2021	BUY	$89.43 - $102.27 $872,747 - $998,052	9,759 Added 66.22%	24,496 $2.38 Million
Q1 2021 May 18, 2021	SELL	$87.57 - $119.4 $645,303 - $879,858	-7,369 Reduced 33.33%	14,737 $1.43 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $70,828 - $107,275	943 Added 4.46%	22,106 $1.91 Million

Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $226,895 - $309,941	2,614 Added 14.09%	21,163 $2.28 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $198,988 - $240,961	-2,374 Reduced 11.35%	18,549 $1.67 Million
Q2 2019 Jul 19, 2019	BUY	$72.24 - $91.27 $1.51 Million - $1.91 Million	20,923 New	20,923 $1.72 Million

628

94.4M

505K

343K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.